Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure

NCT04539366 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04539366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04539366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Suspended
Start date
January 25, 2022
Completion date
December 31, 2040
Enrollment
73 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent childhood neuroblastoma, recurrent childhood osteosarcoma, recurrent neuroblastoma, recurrent osteosarcoma, refractory childhood neuroblastoma, refractory childhood osteosarcoma, refractory neuroblastoma, refractory osteosarcoma